All In MedTech

Device Trial Radar · NCT03733210

Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer

Pilot Study Evaluating Panitumumab-IRDye800 and 89Zr-Panitumumab for Dual-Modality Imaging for Nodal Staging in Head and Neck Cancer

Last checked: Nov 19, 2026Latest source record: May 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

14

Actual

Start

Jan 7, 2019

Primary completion

Dec 11, 2020

Study completion Aug 9, 2021

Sponsor

Lead sponsor
Andrei IagaruAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institutes of Health (NIH); National Cancer Institute (NCI)
First posted
Nov 7, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates how well panitumumab-IRDye800 and 89Zr-panitumumab work in identifying cancer that has spread to the lymph nodes in patients with squamous cell head and neck cancer. Panitumumab-IRDye800 is a drug that contains a dye molecule that fluoresces during surgery to indicate cancerous tissue. 89Zr-panitumumab is a drug that contains a small amount of radiation, which makes it visible in positron emission tomography (PET) scans. PET scans make detailed, computerized pictures of areas inside the body where the drug is used. Giving panitumumab-IRDye800 and 89Zr-panitumumab to patients with head and neck cancer may help doctors find metastatic lymph nodes better than current methods \[positron emission tomography (PET); computed tomography (CT); magnetic imaging resonance (MRI), or combinations\].

Conditions

  • Squamous Cell Carcinoma of the Head and Neck
  • Carcinoma of the Head and Neck

Interventions

  • Panitumumab-IRDye800Drug

    30 mg administered intravenously (IV)

  • 89-Zirconium (Zr-89) PanitumumabDrug

    0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)

  • Pinpoint IR IR9000 fluorescence imaging system (FIS)Device

    Handheld fluorescence-imaging endoscope manufactured by Novadaq

  • SPY-PHI IR9000 fluorescence imaging system (FIS)Device

    Handheld fluorescence-imaging endoscope manufactured by Novadaq

  • Explorer Air cameraDevice

    Fluorescence camera manufactured by SurgVision

  • PDE-NEO II cameraDevice

    Medical infrared camera manufactured by Hamamatsu Photonics KK

  • FIS-00 fluorescence imaging system (FIS)Device

    Fluorescence-imaging system (FIS) manufactured by Hamamatsu Photonics KK

  • Da Vinci Firefly Imaging SystemDevice

    Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc

  • IGP-ELVIS-v4 Macroscopic Specimen ImagerDevice

    Macroscopic specimen imager manufactured by LI-COR Biosciences

  • Vevo 3100 LAZR-XDevice

    Photoacoustic ultrasound imaging system manufactured by VisualSonics

  • Pearl Triology Imaging SystemDevice

    Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences

  • Odyssey CLx Imaging SystemDevice

    Infrared fluorescent-imaging system manufactured by LI-COR Biosciences

  • Leica fluorescence microscopeDevice

    Fluorescence microscope manufactured by Leica

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab LabelingTime frame: up to 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.